Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

2002 • 4,625 citations

Enhancement of Antitumor Immunity by CTLA-4 Blockade

1996 • 3,585 citations

Cancer immunotherapy: moving beyond current vaccines

2004 • 2,932 citations

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

1995 • 2,842 citations

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

1995 • 2,090 citations

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

2002 • 1,853 citations

Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma

2003 • 1,289 citations

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

2008 • 1,184 citations

Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses

2001 • 1,033 citations

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

1999 • 1,000 citations

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

2005 • 997 citations

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

2003 • 981 citations

Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors

1994 • 950 citations

Immune-Mediated Inhibition of Metastases after Treatment with Local Radiation and CTLA-4 Blockade in a Mouse Model of Breast Cancer

2005 • 940 citations

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.

1996 • 917 citations

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner

2005 • 889 citations

Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

2006 • 812 citations

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

2008 • 639 citations

Autoantibody Signatures in Prostate Cancer

2005 • 584 citations

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

2005 • 584 citations

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy

2004 • 571 citations

Control of T‐cell activation by CD4⁺ CD25⁺ suppressor T cells

2001 • 560 citations

Checkpoint Blockade in Cancer Immunotherapy

2006 • 558 citations

Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study

2005 • 486 citations

FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab

2007 • 475 citations

Management and Preparedness for Infusion and Hypersensitivity Reactions

2007 • 467 citations

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

2006 • 437 citations

Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma

2004 • 432 citations

Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance

2005 • 422 citations

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

2000 • 421 citations

Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR

2005 • 406 citations

A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer

2007 • 397 citations

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1997 • 383 citations

CTLA-4 blockade synergizes with tumor-derived granulocyte– macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma

1998 • 375 citations

Cytotoxic T-Lymphocyte-Associated Antigen-4 Blockage Can Induce Autoimmune Hypophysitis in Patients With Metastatic Melanoma and Renal Cancer

2005 • 350 citations

Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?

2006 • 333 citations

Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade

2005 • 331 citations

CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction

2005 • 293 citations

CTLA-4 Blockade Reverses CD8+ T Cell Tolerance to Tumor by a CD4+ T Cell– and IL-2-Dependent Mechanism

1999 • 287 citations

Review: Anti–CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse Events

2007 • 280 citations

Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma

2006 • 261 citations

Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays

2007 • 251 citations

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism

2007 • 249 citations

Differential Roles of Galectin-1 and Galectin-3 in Regulating Leukocyte Viability and Cytokine Secretion

2008 • 245 citations

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

2008 • 242 citations

The Role of CTLA‐4 in the Regulation and Initiation of T‐Cell Responses

1996 • 208 citations

Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)

2008 • 201 citations

Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical Outcome

2005 • 183 citations

Successful Chemotherapeutic Modality of Doxorubicin Plus Dacarbazine for the Treatment of Desmoid Tumors in Association With Familial Adenomatous Polyposis

2005 • 182 citations

Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.

2003 • 181 citations

Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity

2006 • 171 citations

Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

2008 • 159 citations

In vivoblockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance

1999 • 157 citations

Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients

2005 • 143 citations

Myeloid-Derived Suppressor Cells

2007 • 133 citations

Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo

1996 • 132 citations

Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice.

1998 • 129 citations

Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells

1998 • 115 citations

Tumor immune escape mediated by indoleamine 2,3-dioxygenase

2007 • 110 citations

Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.

2005 • 79 citations

High throughput proteomic strategies for identifying tumour-associated antigens

2007 • 73 citations

Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative

2007 • 72 citations

Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer

2006 • 67 citations

Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study

2008 • 47 citations

Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies

2008 • 44 citations

Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma

2007 • 41 citations

Therapy of Disseminated Tumors by Adoptive Transfer of Specifically Immune T Cells1

2015 • 39 citations

Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma

2007 • 39 citations

Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody

2008 • 36 citations

Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies

2008 • 36 citations

The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma

2007 • 36 citations

Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine

2008 • 32 citations

Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma

2008 • 31 citations

Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma

2005 • 30 citations

Potential Target Antigens for Immunotherapy Identified by Serological Expression Cloning (SEREX)

2006 • 30 citations

A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

2008 • 24 citations

Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study

2007 • 20 citations

Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC)

2007 • 15 citations

Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody CP-675,206

2007 • 9 citations

Tumor size, age and stage in patient detected breast cancer

2005 • 8 citations

7005 ORAL Ipilimumab (MDX-010) in patients with stage III/IV melanoma: kinetics and duration of response

2007 • 6 citations

Efficacy of anti-CTLA-4 antibody in the SA1N tumor model when combined with dexamethasone

2007 • 5 citations

Deleted Work

1955 • 0 citations